Presentations on new therapies for hepatitis C virus (HCV) generated the most excitement at CROI 2011. Two new, orally available, direct-acting antivirals, boceprevir and telaprevir, promise to usher in a new era of combination therapy for chronic HCV infection. The antiretroviral drug development pipeline continues to expand, albeit at a slower pace than in recent years.
ASJC Scopus subject areas
- Pharmacology (medical)